Multiple therapy aesthetic treatment device (BHS 202 UNYQUE)
Bh Group Us, LLC · Decision date Sep 22, 2026
What did the FDA decide?
The FDA recorded a substantially equivalent (SESE) decision on 2026-09-22 for K243223, a traditional 510(k) submitted by Bh Group Us, LLC of Davie, Florida, for the Multiple therapy aesthetic treatment device (BHS 202 UNYQUE). The device falls under product code PBX, regulation 21 CFR 878.4400, in the General & Plastic Surgery specialty and review panel. The application was received 10/07/2024 and was not reviewed by a third party; it was not a combination product, and no predetermined change control plan was authorized.
SESE means the device was cleared as substantially equivalent to a predicate, not approved through the PMA pathway. The public record does not state which predicate device was used, the indications for use, the specific therapeutic components or energy modalities of the BHS 202 UNYQUE, or any clinical or performance data supporting the decision. Those details would sit in the linked summary document, which was not reviewed here.
The page also lists Diego Bazzurro as both applicant and correspondent contact, and shows a page update date of 10/26/2026.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 22, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K243223
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Bh Group Us, LLC
- Product code
- PBX
- Decision code
- SESE
- Decision date
- Sep 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Massager, Vacuum, Radio Frequency Induced Heat.
- Applicant
- Bh Group Us, LLC
- Product code
- PBX
- FDA device class
- 2
FDA decision timeline
K243223 received
Application receipt date recorded by FDA.
K243223 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code PBX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Shenzhen Dongdixin Technology Co., Ltd. | 510(k) clearance | Oct 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bh Group Us, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Davie, FL
Sources and methodology
- Original FDA record: K243223
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records